摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(2-amino-4,7-dihydro-5H-thieno[2,3-c]pyran-3-yl)-(p-tolyl)-methanone | 1256257-07-4

中文名称
——
中文别名
——
英文名称
(2-amino-4,7-dihydro-5H-thieno[2,3-c]pyran-3-yl)-(p-tolyl)-methanone
英文别名
3-(4-methylbenzoyl)-4H,5H,7H-thieno[2,3-c]pyran-2-amine;(2-amino-5,7-dihydro-4H-thieno[2,3-c]pyran-3-yl)-(4-methylphenyl)methanone
(2-amino-4,7-dihydro-5H-thieno[2,3-c]pyran-3-yl)-(p-tolyl)-methanone化学式
CAS
1256257-07-4
化学式
C15H15NO2S
mdl
——
分子量
273.356
InChiKey
JEXLMJZPIFTEMP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    533.8±50.0 °C(Predicted)
  • 密度:
    1.280±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.2
  • 重原子数:
    19
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.27
  • 拓扑面积:
    80.6
  • 氢给体数:
    1
  • 氢受体数:
    4

反应信息

  • 作为反应物:
    参考文献:
    名称:
    [EN] INHIBITORS OF HIV REPLICATION
    [FR] INHIBITEURS DE LA RÉPLICATION DU VIH
    摘要:
    本发明涉及新颖的2,3,4-取代的5,6,7,8-四氢[1]苯并噻吩[2,3-b]吡啶化合物及其药用盐,以及含有这些化合物的组合物,以及将这些化合物用作HIV复制抑制剂。
    公开号:
    WO2012066442A1
  • 作为产物:
    描述:
    吡喃-4-酮对甲苯酰乙腈吗啉 、 sulfur 作用下, 以 乙醇 为溶剂, 反应 16.0h, 以36%的产率得到(2-amino-4,7-dihydro-5H-thieno[2,3-c]pyran-3-yl)-(p-tolyl)-methanone
    参考文献:
    名称:
    [EN] INHIBITORS OF HIV REPLICATION
    [FR] INHIBITEURS DE LA RÉPLICATION DU VIH
    摘要:
    本发明涉及新颖的2,3,4-取代的5,6,7,8-四氢[1]苯并噻吩[2,3-b]吡啶化合物及其药用盐,以及含有这些化合物的组合物,以及将这些化合物用作HIV复制抑制剂。
    公开号:
    WO2012066442A1
点击查看最新优质反应信息

文献信息

  • [EN] THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS<br/>[FR] DÉRIVÉS DE LA THIÉNO [2, 3-B] PYRIDINE EN TANT QU'INHIBITEURS DE RÉPLICATION VIRALE
    申请人:UNIV LEUVEN KATH
    公开号:WO2010130842A1
    公开(公告)日:2010-11-18
    The present invention relates to a series of compounds of formula (A) having antiviral activity, more specifically HIV (Human Immunodeficiency Virus) replication inhibiting properties. The invention also relates to methods for the preparation of such compounds, as well as to novel intermediates useful in one or more steps of such syntheses. The invention also relates to pharmaceutical compositions comprising an effective amount of such compounds as active ingredients. This invention further relates to the use of such compounds as medicines or in the manufacture of a medicament useful for the treatment of animals suffering from viral infections, in particular HIV infection. This invention further relates to methods for the treatment of viral infections in animals by the administration of a therapeutical amount of such compounds, optionally combined with one or more other drugs having anti-viral activity.
    本发明涉及一系列具有抗病毒活性的化合物(A)的公式,更具体地说是具有抑制HIV(人类免疫缺陷病毒)复制的特性。该发明还涉及制备这类化合物的方法,以及在这类合成的一个或多个步骤中有用的新中间体。该发明还涉及包含有效量这类化合物作为活性成分的药物组合物。本发明进一步涉及将这类化合物用作药物或用于制造用于治疗患有病毒感染的动物,尤其是HIV感染的药物。本发明还涉及通过给予这类化合物的治疗量,可选地与一个或多个具有抗病毒活性的其他药物结合,来治疗动物的病毒感染的方法。
  • THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS
    申请人:Bardiot Dorothée
    公开号:US20120059028A1
    公开(公告)日:2012-03-08
    The present invention relates to a series of compounds having antiviral activity, more specifically HIV (Human Immunodeficiency Virus) replication inhibiting properties. The invention also relates to methods for the preparation of such compounds, as well as to novel intermediates useful in one or more steps of such syntheses. The invention also relates to pharmaceutical compositions comprising an effective amount of such compounds as active ingredients. This invention further relates to the use of such compounds as medicines or in the manufacture of a medicament useful for the treatment of animals suffering from viral infections, in particular HIV infection. This invention further relates to methods for the treatment of viral infections in animals by the administration of a therapeutic amount of such compounds, optionally combined with one or more other drugs having anti-viral activity.
    本发明涉及一系列具有抗病毒活性的化合物,更具体地说是具有抑制人类免疫缺陷病毒(HIV)复制的特性。本发明还涉及制备这种化合物的方法,以及在这些合成步骤中有用的新型中间体。本发明还涉及含有这种化合物作为活性成分的有效剂量的制药组合物。此外,本发明还涉及将这种化合物用作药物或用于制造对治疗患有病毒感染,特别是HIV感染的动物有用的药物。此外,本发明还涉及通过给予治疗量的这种化合物的管理,可选地与一个或多个具有抗病毒活性的其他药物结合,用于治疗动物的病毒感染的方法。
  • Inhibitors of HIV Replication
    申请人:Bell Andrew Simon
    公开号:US20120136023A1
    公开(公告)日:2012-05-31
    The present invention relates to novel 2,3,4-substituted 5,6,7,8-tetrahydro[1]benzothieno[2,3-b]pyridine compounds and pharmaceutically acceptable salts thereof, to compositions containing such compounds and to the use of such compounds as inhibitors of HIV replication.
    本发明涉及新颖的2,3,4-取代的5,6,7,8-四氢[1]苯并噻吩[2,3-b]吡啶化合物及其药学上可接受的盐,以及含有这种化合物的组合物和将这种化合物用作HIV复制抑制剂的用途。
  • Thieno [2, 3-B] pyridine derivatives as viral replication inhibitors
    申请人:Bardiot Dorothée
    公开号:US08785638B2
    公开(公告)日:2014-07-22
    The present invention relates to a series of compounds having antiviral activity, more specifically HIV (Human Immunodeficiency Virus) replication inhibiting properties. The invention also relates to methods for the preparation of such compounds, as well as to novel intermediates useful in one or more steps of such syntheses. The invention also relates to pharmaceutical compositions comprising an effective amount of such compounds as active ingredients. This invention further relates to the use of such compounds as medicines or in the manufacture of a medicament useful for the treatment of animals suffering from viral infections, in particular HIV infection. This invention further relates to methods for the treatment of viral infections in animals by the administration of a therapeutic amount of such compounds, optionally combined with one or more other drugs having anti-viral activity.
    本发明涉及一系列具有抗病毒活性的化合物,更具体地说是具有抑制人类免疫缺陷病毒(HIV)复制的性质。本发明还涉及制备这种化合物的方法,以及在这些合成步骤中有用的新中间体。本发明还涉及包含这种化合物作为活性成分的有效量药物组合物。本发明进一步涉及将这种化合物用作药物或制造药物,用于治疗患有病毒感染的动物,特别是HIV感染。本发明还涉及通过给予这种化合物的治疗剂量,可选地与一种或多种具有抗病毒活性的其他药物联合使用,治疗动物的病毒感染的方法。
  • THIENO[2,3-B]PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS
    申请人:Katholieke Universiteit Leuven
    公开号:EP2430029B1
    公开(公告)日:2018-01-10
查看更多